University of Minnesota Efforts to Optimize Anticoagulant use in COVID-19 Patients

Soon after the COVID-19 Pandemic began in early 2020, the University of Minnesota (MHealth Fairview)Team recognized the importance of hypercoagulability in COVID-19 and wanted to provide evidence-based support for decisions about using anticoagulation for patients in their healthcare system hospitalized with COVID-19. They sought to do this in a 'learning health system' context that would optimize the cycle from evidence to guidance to action to data and back to evidence. They worked closely with the ACTS initiative and others to support these efforts. Their activities and collaborations can be a springboard for broadly enhancing knowledge ecosystem function in a target-focused manner across many targets and settings, as outlined in the ACTS LHS Proposal.

Below is a DRAFT/UNVETTED overview of UMN's LHS efforts for anticoagulation in COVID-19 patients. The purposes for sharing this information here are to illustrate how 1) initiatives such as the ACTS COVID-19 Evidence to Guidance to Action Collaborative can support target-focused LHS enhancement efforts within and across stakeholder organizations and 2) this work can provide a model that can be adapted to build on work and collaborations producing the ACTS LHS Concept Demonstration to advance the ACTS LHS Proposal.